ADTKD-MUC1 Screening & Consensus Guidelines

Consensus recommendations, quality benchmarks, and screening decision pathways for MUC1 VNTR mutation detection in chronic kidney disease (ADTKD-Net).

Overview & Genetic Etiology

Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD-MUC1, ORPHA:65289) leads to progressive renal failure with bland urinary sediment, minimal proteinuria, and unremarkable early renal ultrasound. Affected individuals commonly present with early hyperuricemia and gout, reaching end-stage kidney disease (ESKD) between ages 30 and 70.

The pathogenic mechanism is a +1 frameshift in the GC-rich (~82%) 60-bp variable number tandem repeat (VNTR) of MUC1 exon 2. The resulting neoprotein, MUC1-fs, accumulates intracellularly in renal tubular cells, triggering chronic proteotoxic stress and tubulointerstitial fibrosis. While the canonical 59dupC variant accounts for ~84% of cases, international ADTKD-Net screening identified that ~16% of confirmed patients carry non-canonical (non-dupC) frameshifts across the repeat. These variants are invisible to 59dupC-targeted minisequencing (SNaPshot) and standard NGS alignment pipelines.

Consensus Screening & Clinical Pathways

The European ADTKD-Net consortium established two clinical pathways integrating computational short-read genotyping (VNtyper 2) into clinical practice:

Pathway 1

Secondary Screening in Unexplained CKD (CKDx)

Patients undergoing diagnostic exome, genome, or panel sequencing for unexplained CKD can be screened computationally with VNtyper 2 on existing BAM/CRAM alignments at zero additional wet-lab cost.

Pathway 2

High-Suspicion Targeted Evaluation

In patients with dominant familial tubulointerstitial disease or biopsy-proven interstitial fibrosis, exome or panel sequencing with VNtyper 2 serves as the initial computational step. If negative despite strong clinical suspicion, dedicated orthogonal testing (long-read sequencing or SNaPshot) must follow.

Consensus screening workflow for ADTKD-MUC1. Short-read NGS data is analyzed computationally via VNtyper 2. Results are classified into three actionable tiers. High Precision findings support clinical reporting. Uncertain results and negative calls with strong clinical suspicion proceed to dedicated confirmatory modalities.

Interpretation Tiers & Clinical Actions

Interpretation Tier	Screening Criteria	Recommended Action
High Precision Reportable	Concordant variant callers (Kestrel and adVNTR), high alternate k-mer support score, and mean VNTR coverage ≥100× (≤50% uncovered positions).	Supports diagnostic reporting per accredited laboratory protocol. Orthogonal confirmation is optional, recommended for reproductive counselling or living kidney donor evaluations.
Uncertain Confirmation Needed	Low Precision (LP) score, caller discordance, or regional coverage <100×.	Non-definitive result. Mandatory orthogonal confirmation (long-read sequencing preferred) before clinical reporting.
Negative Context Dependent	Absence of frameshift k-mers and HMM-supported insertion.	If mean depth ≥100×, ADTKD-MUC1 is excluded with high confidence. If familial or clinical suspicion remains high, pursue orthogonal long-read testing or SNaPshot.

Comparison of Testing Modalities

Modality	Variant Spectrum	Input Specimen	Turnaround	Role & Considerations
VNtyper 2 Online	59dupC + non-dupC (~100%)	Short-read NGS (BAM, CRAM, FASTQ)	<3 minutes	First-line computational screening; zero wet-lab cost; depends on capture kit coverage.
SNaPshot Minisequencing	Canonical 59dupC only (~84%)	Genomic DNA (blood/saliva)	1–2 weeks	Established targeted confirmation for 59dupC; inherently blind to ~16% non-dupC variants.
Long-Read (PacBio / ONT)	All variants + full VNTR length	HMW genomic DNA	2–4 weeks	Definitive reference standard; resolves complex non-dupC alleles and repeat structure.
MUC1-fs Staining	Intracellular neoprotein	Kidney biopsy or urinary cells	1–3 days	Phenotypic confirmation when DNA is unavailable or genetic findings are discordant.

Sequencing Quality & Exome Capture Recommendations

Detection accuracy in the GC-rich VNTR depends on the library preparation design and sequencing depth:

Twist Exome v2 & IDT xGen Exome v1/v2 (Recommended): Probe overlap across the VNTR repeat provides stable calling down to ~80× regional coverage.
Agilent SureSelect v8 (Caveat): Omits repeat probes; negative calls with this design are uninformative.
Quality Thresholds: Diagnostic interpretation requires mean regional VNTR depth ≥100× and ≤50% uncovered positions.

Accredited Testing Centers & ADTKD-Net Laboratories

Institution	Location	Testing & Screening Capabilities	Reference Link
Institut Imagine	Paris, France	VNtyper short-read pipeline, targeted gene panels, WES	institutimagine.org
Labor Berlin – Charité Vivantes	Berlin, Germany	Short-read screening, accredited diagnostic reporting	laborberlin.com
Institute of Human Genetics Erlangen	Erlangen, Germany	Illumina short-read NGS, MUC1-fs biopsy staining	uk-erlangen.de
Charles University Rare Disease Unit	Prague, Czech Republic	PacBio long-read sequencing, SNaPshot, urinary cell immunofluorescence	cuni.cz
Wake Forest University School of Medicine	Winston-Salem, NC, USA	SNaPshot minisequencing, international ADTKD registry	wakehealth.edu

Patient Advocacy & Registries

ADTKD-Selbsthilfe e.V.: German patient advocacy organization providing guidance and educational resources (adtkd.de).
ERKNet ADTKD Registry: European Rare Kidney Disease Reference Network international patient registry (erknet.org).

Screen Alignments Online

Screen short-read sequencing data directly in your web browser. Target region extraction executes client-side via WebAssembly without uploading raw sequencing files.

Launch VNtyper Online →